Regulus Therapeutics Inc.
RGLS
Kedudukan dalam Saham
#17331
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Harga Saham
$8.16
Disegerakkan terakhir: 2025-06-26
Modal Pasaran
$234.57M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-56.96%
Negara
US
Perdagangan Regulus Therapeutics Inc. (RGLS)
Kategori
Healthcare
Hasil untuk Regulus Therapeutics Inc. (RGLS)
Hasil pada Mar 2024 TTM: $219.60M
Menurut laporan kewangan terkini daripada Regulus Therapeutics Inc., hasil semasa syarikat (TTM) ialah $219.60M. Pada tahun 2022, syarikat memperoleh hasil sebanyak $298.49M peningkatan berbanding hasil pada tahun 2021 iaitu $204.23M. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Regulus Therapeutics Inc. dari 2002 hingga 2026
Hasil pada akhir setiap tahun
| Tahun | Hasil | Ubah |
|---|---|---|
| 2026 (TTM) | $219.60M | -16.63% |
| 2023 | $263.41M | -11.75% |
| 2022 | $298.49M | 46.15% |
| 2021 | $204.23M | -48.83% |
| 2020 | $399.10M | 395.72% |
| 2019 | $80.51M | -8.35% |
| 2018 | $87.84M | 9.61% |
| 2017 | $80.14M | 53.12% |
| 2016 | $52.34M | -54.62% |
| 2015 | $115.34M | 49.00% |
| 2014 | $77.41M | -27.79% |
| 2013 | $107.21M | 56.55% |
| 2012 | $68.48M | -47.51% |
| 2011 | $130.46M | 12.11% |
| 2010 | $116.37M | 0.16% |
| 2009 | $116.18M | 16.36% |
| 2008 | $99.85M | 10.24% |
| 2007 | $90.57M | 29.80% |
| 2006 | $69.78M | 640.17% |
| 2005 | $9.43M | -68.37% |
| 2004 | $29.80M | 54.60% |
| 2003 | $19.28M | 9.63% |
| 2002 | $17.58M | 0.00% |
Hasil untuk syarikat atau pesaing serupa
| Syarikat | Hasil | Perbezaan Hasil | Negara |
|---|---|---|---|
| $12.62B | 5,648.72% |
US
|
|
| $2.23B | 914.56% |
US
|
|
| $15.74B | 7,069.48% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 2,641.91% |
NL
|
